BrainsWay Ltd. (BWAY)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 2
Do Nothing: average 20-day dollar volume ~$1.39M is below the $5M liquidity floor and the recent 3-session average ~$1.32M is below the $1.5M recent-liquidity floor - too thin to trade at size; no entry qualifies (a pullback limit would additionally fail the countertrend check: price < SMA50 with MACD < 0; no breakout stop exists with price under the full moving-average stack).
Company overview
BrainsWay Ltd. develops non-invasive neurostimulation therapies for mental health and neurological conditions. Its primary technology, Deep Transcranial Magnetic Stimulation (dTMS), treats disorders such as depression, OCD, and addiction. The company operates globally, serving medical professionals and institutions.
Fundamental
fairBrainsWay shows strong growth and profitability but faces valuation and event risks.
BrainsWay combines accelerating growth (+27% FY2025, ~+35% H1 2026), ten straight profitable quarters, ~75% gross margins and a net-cash balance sheet (no bank debt, no going-concern or covenant issues in SEC filings) with a demanding valuation (~49x trailing earnings, ~32x EV/EBITDA, ~1.1% FCF yield) and real headline risks (Magnus IP letter, Middle East conflict, customer concentration). Analyst consensus price target of $19.50 sits well above the $11.46 quote. Verdict: high-quality operator at a rich price - mixed/uncertainty overall, with the caution driven by valuation and event risk rather than business quality.
Sentiment
fairSentiment has cooled from a post-earnings high, with recent news not yet stabilizing the stock.
Dominant near-term catalyst is the announced 2026-10-13 SWIFT Accelerated Deep TMS U.S. coverage expansion past 70M covered lives (material, announced, not yet priced in), landing against a determinate cooling in sentiment (baseline polarity ≈ +0.45, scoring ≈ +0.13; delta ≈ -0.32) and a soft two-week tape. Red-Flag Screen clean — no severe or moderate flags fired — and with no forward-dated event on the calendar the setup reads genuinely mixed rather than one-sided.
Technical
weakThe stock is oversold with a weak-bearish trend and insufficient liquidity for trading.
Oversold but structurally weak: price 11.46 trades below SMA20 12.83, SMA50 14.05, SMA200 13.85 and under the EMA9/EMA21 stack (12.04/12.74); RSI14 25.66 and Williams %R -96.69 are deeply oversold while MACD -0.70/-0.58 (histogram -0.12) stays negative and ADX14 18.64 shows no strong trend - a bounce-only tape. The trade is blocked regardless: avgDollarVolume20 ~$1.39M is below the $5M liquidity floor and the recent 3-session average ~$1.32M is below the $1.5M recent-liquidity floor.
You’re looking at 2026-10-13 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

